A Randomized, Placebo-Controlled, Double-Blind Study of XPro1595 in Patients With Early Alzheimer's Disease With Biomarkers of Inflammation
Latest Information Update: 28 Jun 2024
At a glance
- Drugs Pegipanermin (Primary)
- Indications Alzheimer's disease
- Focus Proof of concept; Therapeutic Use
- Acronyms MINDFuL
- Sponsors INmune Bio
- 27 Jun 2024 According to an INmune Bio media release, interim analysis, performed by a third-party, demonstrated no need to change trial design or size.
- 27 Jun 2024 Interim analysis results published in the INmune Bio Media Release
- 09 May 2024 According to an INmune Bio media release, company anticipates having its Phase II FDA meeting in the first half of 2025 before transitioning to the global Phase III trial in the latter portions of next year.